Allergan and the Saint Regis Mohawk Tribe have again urged the US Supreme Court to hear their closely-followed litigation on tribal sovereign immunity, following a submission from generic maker Mylan in the case.
Danish pharmaceutical company Novo Nordisk and generics maker Teva have reached a settlement in their US dispute over Victoza.
Supranational organisations such as the World Health Organization and the United Nations Development Program are promoting acts, policies and practices that prevent biopharmaceutical innovators from securing and maintaining patents.
The Trump administration has named Ned Sharpless, director of the National Cancer Institute, as the Food and Drug Administration's (FDA) acting commissioner.
Scott Gottlieb, commissioner of the US Food and Drug Administration, resigned from his post yesterday, March 5, with plans to step down in the next month.
The patents division of the English High Court has found that a patent owned by Genentech is invalid and denied the biotechnology company’s application for a supplementary protection certificate.
The US Federal Trade Commission concluded a ten-year pay-for-delay suit yesterday, with AbbVie agreeing not to enter certain settlements in patent cases that delay market entry of generic drugs.
A jury has upheld two of Amgen’s patents for its cholesterol drug Repatha, rejecting a challenge brought by two competitors.
Indivior has launched a generic version of its opioid addiction drug Suboxone (buprenorphine and naloxone) Film, one day after the US Supreme Court denied its request to put a lower court’s ruling on hold.
Teva Pharmaceutical and the US Federal Trade Commission have reached a settlement to end their long-running battles over so called “pay-for-delay” agreements in the pharmaceutical industry.